Incyte Corp. (INCY)
127.99
+0.18
(+0.14%)
USD |
NASDAQ |
Aug 24, 16:00
127.99
0.00 (0.00%)
After-Hours: 19:20
Incyte Price to Book Value : 4.054 for Aug. 24, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 4.049 |
| August 20, 2026 | 4.030 |
| August 19, 2026 | 4.070 |
| August 18, 2026 | 3.911 |
| August 17, 2026 | 3.912 |
| August 14, 2026 | 3.806 |
| August 13, 2026 | 3.818 |
| August 12, 2026 | 3.826 |
| August 11, 2026 | 3.835 |
| August 10, 2026 | 3.850 |
| August 07, 2026 | 3.819 |
| August 06, 2026 | 3.75 |
| August 05, 2026 | 3.795 |
| August 04, 2026 | 3.820 |
| August 03, 2026 | 3.752 |
| July 31, 2026 | 3.786 |
| July 30, 2026 | 3.896 |
| July 29, 2026 | 4.026 |
| July 28, 2026 | 4.116 |
| July 27, 2026 | 3.766 |
| July 24, 2026 | 3.728 |
| July 23, 2026 | 3.696 |
| July 22, 2026 | 3.668 |
| July 21, 2026 | 3.719 |
| July 20, 2026 | 3.664 |
| Date | Value |
|---|---|
| July 17, 2026 | 3.714 |
| July 16, 2026 | 3.695 |
| July 15, 2026 | 3.646 |
| July 14, 2026 | 3.639 |
| July 13, 2026 | 3.619 |
| July 10, 2026 | 3.697 |
| July 09, 2026 | 3.754 |
| July 08, 2026 | 3.714 |
| July 07, 2026 | 3.740 |
| July 06, 2026 | 3.663 |
| July 02, 2026 | 3.702 |
| July 01, 2026 | 3.605 |
| June 30, 2026 | 3.591 |
| June 29, 2026 | 4.077 |
| June 26, 2026 | 4.045 |
| June 25, 2026 | 3.824 |
| June 24, 2026 | 3.857 |
| June 23, 2026 | 3.712 |
| June 22, 2026 | 3.686 |
| June 18, 2026 | 3.493 |
| June 17, 2026 | 3.520 |
| June 16, 2026 | 3.547 |
| June 15, 2026 | 3.626 |
| June 12, 2026 | 3.859 |
| June 11, 2026 | 3.834 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Mirum Pharmaceuticals, Inc. | -- |
| Regeneron Pharmaceuticals, Inc. | 2.702 |
| BioMarin Pharmaceutical, Inc. | 1.991 |
| Eli Lilly & Co. | 34.67 |
| Biogen, Inc. | 1.709 |
Price to Book Value Related Metrics
| PE Ratio | 16.31 |
| PS Ratio | 4.515 |
| PEG Ratio | 0.2081 |
| Price to Free Cash Flow | 13.90 |
| Price | 127.99 |
| Earnings Yield | 6.13% |
| Market Cap | 25.72B |
| PEGY Ratio | 0.2081 |
| Operating PE Ratio | 14.28 |
| Normalized PE Ratio | 16.06 |